Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05202145 · ClinicalTrials.gov registry record · Phase 1

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

A Phase 1 study of Healthy, sponsored by Alexion Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
61
Enrollment target
1
Study location

NCT05202145 is a Phase 1 study of Healthy that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 61 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05202145, a Phase 1 study of Healthy, has completed, sponsored by Alexion Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
61 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the potential drug interactions between ALXN2050 and cyclosporine (Part 1), between ALXN2050 and tacrolimus (Part 2), and between ALXN2050 and mycophenolate mofetil (MMF) (Part 3).

Conditions Studied

Healthy

Interventions

  • DRUG Tacrolimus
  • DRUG Cyclosporine
  • DRUG MMF
  • DRUG ALXN2050

Study Locations (1)

Arizona

  • Clinical Study Site - Tempe

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2022-01-11
Est. Completion 2022-03-21
Phase Phase 1

Sponsor

Alexion Pharmaceuticals

162 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05202145

The ClinicalTrials.gov registry entry for NCT05202145 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Tacrolimus is the first listed.

NCT05202145 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT05202145 about?

NCT05202145 is a clinical study titled "Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants". This study will evaluate the potential drug interactions between ALXN2050 and cyclosporine (Part 1), between ALXN2050 and tacrolimus (Part 2), and between ALXN2050 and mycophenolate mofetil (MMF) (Part 3).

What is the current status of trial NCT05202145?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2022-01-11. Estimated completion is 2022-03-21.

What conditions does trial NCT05202145 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT05202145?

The interventions under investigation include: Tacrolimus (DRUG), Cyclosporine (DRUG), MMF (DRUG), ALXN2050 (DRUG).

Who is sponsoring clinical trial NCT05202145?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05202145 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.